

PROGRAMME AT A GLANCE

Time (CEST)	Wednesday 5 May 2021	Thursday 6 May 2021	Friday 7 May 2021
09:30-14:30	Side-meetings: 09:30-11:00 EATG stakeholder meeting regarding diagnostics 11:30-13:00 Lisbon Fast Track City 13:30-14:30 European Fast-Track Cities	Side-meeting: 10:00-13:00 CET, COBATEST network executive meeting, Closed meeting	
13:00-14:15		Plenary/abstract-driven session: Impact of COVID-19 on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building back better	Plenary session: Implementing integrated testing strategies
14:30-15:30	15:00-17:00 Opening session	Abstract driven session: The use of new technologies to increase testing coverage	Abstract driven session: Models of testing and linkage to care for PWID and PWUD
15:30-16:30		E-poster sessions (live Q&A)/Break	E-poster sessions (live Q&A)/Break
16:30-17:45		Plenary session: Combination prevention in HIV, viral hepatitis, STIs and TB	Plenary session: Special Session on people who inject/use drugs (EMCDDA/ECDC)
18:00-19:30		18:00-19:30 EU Health Project Symposium: lessons learned from INTEGRATE	18:00-19:15 Closing session: Integrating disease areas and settings: Paving the way forward

Wednesday 5 May 2021			
Time (CEST)	Side meetings		
09:30-11:00	EATG stakeholders meeting regarding diagnostics		
11:30-13:00	Lisbon Fast Track City: HCV testing and treatment in the community – learning from harm reduction and people who use drugs		
13:30-14:30	Fast-Track Cities: Actioning HCV Elimination in European Urban Settings		
Time (CEST)	Prese- n- tation No.	Session	Moderators and speakers
15:00-17:00	OS	OPENING SESSION Session objectives: To provide an overview of the conference objectives, scope and expected outcomes of the conference. Set the scene through policy, technical and community perspectives on European progress toward the Sustainable Development Goals and other global targets, including challenges ahead and priorities for maintaining HIV, viral hepatitis, STIs and TB on the political agenda.	Moderators: Daniel Simões, HepHIV2021 Conference Co-chair, Coalition Plus/GAT, Portugal Jürgen Rockstroh, HepHIV2021 Conference Co-chair, HIV Outpatient Clinic, University of Bonn, Germany
15:00-15:10	OS/00	Welcome to the HepHIV 2021 Lisbon & Virtual Conference	Ricardo Baptista Leite, Local conference co-chair, MP Portugal, UNITE
15:10-15:20	OS/01	Conference objectives and overview	Dorthe Raben, EuroTEST Initiative, CHIP, University of Copenhagen
15:20-15:30	OS/02	Welcome message from the Portuguese Minister of Health	António Lacerda Sales, Assistant State Secretary for Health, Portugal
15:30-15:40	OS/03	Welcome from the European Commission: The EU response on HIV, viral hepatitis, STIs and TB in the future	John Ryan, Director of Public Health, DG Sante, European Commission
15:40-15:50	OS/04	Post-2020/COVID-19 and progress towards the SDG targets: Where are we?	Andrea Ammon, Director, European Centre for Disease Prevention and Control (ECDC)
15:50-16:00	OS/05	'The changed landscape' – providing testing for HIV/STIs/hepatitis/TB in the era of COVID-19	Hans Kluge, Regional Director, WHO Regional Office for Europe. <i>Represented by Nicole Seguy, WHO Regional Office for Europe in the live discussion</i>
16:00-16:10	OS/06	Country Spotlight: Portugal's progress in reaching the global targets and interventions for integration of testing	Rui Portugal, Deputy Director-General of Health, National Directorate of the Portuguese Ministry
16:10-16:20	OS/07	Community perspective on enabling environments for integrated testing and linkage to care across Europe	Daniel Simões, Coalition Plus/GAT, Portugal
16:20-17:00		Panel discussion	

Thursday 6 May 2021			
Time (CEST)		Session	Moderators and speakers
13:00-14:15	PS1	PLENARY SESSION 1: SPECIAL SESSION: Impact of COVID-19 on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building back better Session objectives: To share the latest evidence of how the COVID-19 pandemic has impacted prevention, testing and linkage to care for HIV, viral hepatitis and STIs; share successful models of service adaptation and discuss how to build stronger systems and communities in light of lessons learned.	Moderators: Nicole Seguy, WHO Regional office for Europe Jeffrey Lazarus, Barcelona Institute for Global Health (IS Global)
13:00-13:10	PS1/01	Keynote address: Perspectives from the US National Institute of Allergy and Infectious Diseases of the National Institutes of Health	H.Clifford Lane, Deputy Director for Clinical Research and Special Projects , National Institute of Allergy and Infectious Diseases (NIAID), USA
13:10-13:20	PS1/02	Impact of the COVID-19 pandemic on testing and linkage to care for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region	A.R. Stengaard ¹ , A. Sullivan ² , J.D Kowalska ³ , C. Rokx ⁴ , D. Raben ¹ , D. Simões ⁵ , The EuroTEST COVID-19 impact assessment consortium of partners
13:20-13:30	PS1/03	s.a.m. Health: Germany's first digital sexual health service is providing COVID-safe remote STI testing and counselling during the Covid-19 Pandemic and beyond	A. Schafberger ¹ , K.M. Dymek ² , G. Waltinger ³ , G. Davies ⁴ , C. Kantwerk ¹
13:30-13:40	PS1/04	Rapid HIV testing and linkage in rehabilitation centers during COVID-19 pandemics, Yekaterinburg and Sverdlovsk region, Russia	V. Evseeva ¹ , M. Greysman ¹ , V. Stanilevskiy ² , N. Mironova ² , A. Chuykov ³ , A.M. Żakowicz ³
13:40-13:50	PS1/05	European testing week: adaptation of testing services during the COVID-19 pandemic	B. Collins ¹ , C. Bom Kahama ² , D. Raben ²
13:50-14:15		Discussion	
14:15-14:30		Break	
14:30-15:30	AS1	ABSTRACT DRIVEN SESSION 1: The use of new technologies to increase testing coverage Session objectives: To share innovative programmes and experiences for implementing new testing and sampling technologies to increase HIV, viral hepatitis, STI and TB testing coverage based on submitted conference abstracts.	Moderators: Cary James, World Hepatitis Alliance Valerie Delpech, Public Health England
14:30-14:37	AS1/01	RiskRadar: the 1st integrated ICT tool on combination prevention for hepatitis/HIV/TB/STI	L. Cosmaro ¹ , D. Savarino ¹ , M. Mommi ² , Z. Dominkovic ³ , A. Simkunaite-Zazecke ⁴ , L. Stoniene ⁵ , A. Raahauge ⁶ , C. Kakalou ⁷ , V. Drosou ⁸ , P. Natsiavas ⁷
14:37-14:44	AS1/02	An evaluation of the outcomes of an online HIV self-sampling service to inform risk communication and future online testing policy	J. Taylor ^{1,2} , G. Holdsworth ¹ , S. Amos-Gibbs ¹ , E. Ardines ¹ , B. George ¹ , J. Harbottle ¹ , P. Baraitser ^{1,3}
14:44-14:51	AS1/03	Efficacy of an on-screen computer reminder for HIV screening in primary care based on indicator conditions: a cluster randomized controlled trial	C. Agusti ^{1,2} , O. Cunillera ³ , J. Almeda ³ , J. Mascort ^{4,5} , R. Carrillo ^{4,5} , C. Olmos ³ , J. Casabona ^{1,2}
14:51-14:58	AS1/04	Breaking the Chain? A once in a generation opportunity to find and treat HIV during UK's COVID-19 lockdown	A. Basu ¹ , B. George ¹ , G. Holdsworth ¹
14:58-15:30		Discussion	

15:30-16:30		E-poster sessions (live Q&A)/break: PO1: Innovative testing services during the COVID-19 pandemic: lessons learned PO2: Impact of COVID-19 on provision of services for people who inject/use drugs PO3: New testing technologies to increase testing coverage: HIV self-testing and home-based sampling	
16:30-17:45	PS2	PLENARY SESSION 2: Combination prevention in HIV, viral hepatitis, STIs and TB Session objectives: To share advances in prevention programming; define the concept of combination prevention in HIV, hepatitis, STIs and TB, highlighting good examples of how combination prevention can be implemented as a strategy and enlarged as a people-centered approach.	Moderators: Ben Collins, ReShape/International HIV Partnerships Teymur Noori, European Centre for Disease Prevention and Control (ECDC)
16:30-16:40	PS2/01	“Prevention is hard, Combination is key” – Good example of HIV/STI combination prevention in Scotland	Claudia Estcourt, Glasgow Caledonian University, Scotland, United Kingdom
16:40-16:50	PS2/02	Combination disease prevention in prisons: a comprehensive programme in Luxembourg	Patrick Hoffmann, Luxembourg Directorate of Health
16:50-17:00	PS2/03	TB an HBV/HCV/HIV-combined preventive activities in the Netherlands	Gerard de Vries, RIVM, Netherlands
17:00-17:10	PS2/04	The ‘Get Tested LeEDs’ project: clinical impact and cost-effectiveness of opt-out emergency department testing for bloodborne viruses (BBVs) in England	E. Smout ¹ , J. Williams ² , A. Miners ² , K. Phyu ³ , L Parker ³ , A Evans ³ , J McLaren ³ , M. Aldersley ³ , G. Hughes ¹ , M. Ruf ⁴ , E. Page ³
17:10-17:45		Discussion	
17:45-18:00		Break	
18:00-19:30		EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action Session objectives: To discuss integration of infectious diseases and ways to ensure sustainability and improvement of integrated health care models.	Moderators: Luis Mendão, GAT Portugal Dorthe Raben, CHIP/INTEGRATE Coordinator
18:00-18:05		The INTEGRATE Story & INTEGRATE at HepHIV	Dorthe Raben, CHIP/INTEGRATE Coordinator
18:05-18:30		Video presentation of the processes behind the main outcomes of the INTEGRATE JA Short intro to the Online training module on prevention, testing and linkage to care	
18:30-19:30		Panel discussion: Integration of Infectious Diseases – keeping the momentum	Valerie Delpech, Public Health England, UK Lella Cosmaro, Lila Milano, Italy Jordi Casabona, El Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Catalonia, Spain Ann Sullivan, SSAT Chelsea Westminster Hospital, UK Nadia Gasbarrini, Villa Maraini, Italy Jack Lambert, University of Dublin & Mater Misericordiae University Hospital, Ireland Walter Cullen, University of Dublin, Ireland Jeff Lazarus, Barcelona Institute for Global Health (IS Global), Catalonia, Spain

			<p>Teymur Noori, European Centre for Disease Prevention and Control (ECDC) Thomas Seyler, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Ana Gutierrez Burgos, European Commission, DG SANTE</p>
--	--	--	--

Friday 7 May 2021			
Time (CEST)		Session	Moderators and Speakers
13:00-14:15	PS3	PLENARY SESSION 3: Implementing integrated testing strategies Session objectives: To present examples of innovative integrated testing programmes for HIV, viral hepatitis, STIs and/or TB and highlight effective implementation models of integrated testing and linkage to care at different service levels.	Moderators: Jordi Casabona, El Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Catalonia, Spain Anastasia Pharris, European Centre for Disease Prevention and Control (ECDC)
13:00-13:10	PS3/01	Experience in innovative approach to testing for HIV, hepatitis and STIs	Raimonda Matulionytė, Vilnius University Hospital Santaros Klinikos, Lithuania
13:10-13:20	PS3/02	Integrated screening for TB, HIV and HCV at the primary healthcare level	Maka Danelia, National Center for Disease Control and Public Health, Georgia
13:20-13:30	PS3/04	Evolution of key indicators for community-based voluntary counseling and testing activity in Europe: COBATEST Network 2017-2019	M. Gogishvili ¹ , L. Fernández López ^{1,2,3} , J. Casabona Barbarà ^{1,2,3}
13:30-13:40	PS3/05	Implementing self-test programmes during COVID-19	Robert Hejzák, Czech AIDS Help Society
13:40-14:15		Discussion	
14:15-14:30		Break	
14:30-15:30	AS2	ABSTRACT DRIVEN SESSION 2: Models of testing and linkage to care for PWID and PWUD Session objectives: To share and discuss experiences in implementing testing and care models for people who inject or use drugs and provide European and global overviews of harm reduction and care responses (for people who inject or use drugs), including responses to the global COVID-19 pandemic.	Moderators: Eberhard Schatz, Correlation Network Lella Cosmaro, Lila Milano, Italy
14:30-14:37	AS2/01	Testing and linkage to care services for 1000 people who inject drugs from Bucharest through the implementation of a three level HCV elimination strategy	S. Ciobanu ¹ , A. Bocai ¹ , M. Dan ¹ , A. Luca ¹ , R. Teodorescu ¹
14:37-14:44	AS2/02	Integrated harm reduction responses to HIV and viral hepatitis in the COVID-19 pandemic: a global overview	S. Shirley-Beavan ¹ , R. Csak ¹ , C. Daniels ¹ , N. Burke-Shyne ¹ , G. Lasco ² , M. Platko ³ , J. di Iorio ⁴ , C. Ahumada ⁴ , S. Hajal ⁵ , E. Aaraj ⁵ , C. Baguma ⁶ , K. Naik ⁷
14:44-14:51	AS2/03	Feasibility of HCV micro-elimination: HCV test and treatment in two harm reduction services in Milan, Italy	S. Mazzilli ^{1,2} , T. Sebastiani ³ , V. Casigliani ¹ , G. Cocca ³ , A. Stemat ³ , C. Nicola ³ , C. Selva ³ , C. Catani ³ , L. Tavoschi ¹ , R. Ranieri ³
14:51-14:58	AS2/04	Blood-borne virus testing in people who inject drugs with a history of sex work	E. Emanuel ¹ , S. Croxford ¹ , E. Phipps ¹ , A. Ibitoye ¹ , J. Njoroge ¹ , C. Edmundson ¹ , L. Slater ¹
14:58-15:05	AS2/05	HCV care for PWID in Europe - results from a civil society-led monitoring	R. Rigoni ¹ , T. Tammi ² , E. Schatz ¹
15:05-15:30		Discussion	

15:30-16:30		E-poster sessions (live Q&A)/Break: PO4: Integrated testing programmes for hepatitis/HIV/TB/STI: health care settings PO5: Integrated testing programmes for hepatitis/HIV/TB/STI: community-based settings PO6: Models of testing and linkage to care for people who inject/use drugs	
16:30- 17:45	PS4	PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC) Session objectives: To provide an overview of the latest evidence on prevention, testing and linkage to care for people who use or inject drugs, highlighting the importance of prison settings for increasing diagnosis and care for people who inject drugs, and to discuss the impact of COVID-19 on the provision of services for people who use drugs.	Moderators: Anne Bergenström, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Viktor Mravčík, Head of the National Monitoring Centre for Drugs and Addictions, Czechia
16:30-16:40	PS4/01	Keeping the HIV/Hepatitis targets for PWID on track during the Covid-19 pandemic: European perspectives	Thomas Seyler, EMCDDA
16:40-16:50	PS4/02	New evidence on testing and linkage to care for PWIDs	Otilia Mardh, European Centre for Disease Prevention and Control (ECDC)
16:50-17:00	PS4/03	Ensuring delivering of testing and linked services for PWID/PWUD during the COVID19 pandemic	Marios Atzemis, Positive Voice, Greece
17:00-17:10	PS4/04	What is needed to promote prisons as a setting for case-finding and treatment of infections among PWIDs?	Fadi Meroueh, Montpellier University Hospital, France
17:10-17:45		Panel Discussion	Moderator: Linda Montanari, EMCDDA
17:45-18:00		Break	
18:00-19:15		CLOSING SESSION: Integrating disease areas and settings Session objectives: To discuss lessons learned and next steps for integration of service delivery in infectious diseases; to present and discuss the Conference Call to Action and implications for policy and implementation agendas.	Moderator: Michel Kazatchkine, Special Advisor to the Joint United Nations Program on AIDS (UNAIDS) for Eastern Europe and Central Asia
18:00-18:15		Short report from Conference Days 1 and 2 and Best Poster Award	Jürgen Rockstroh, HepHIV2021 Conference Co-chair, HIV Outpatient Clinic, University of Bonn, Germany
18:15-19:05		Panel Discussion: Integrated testing and linkage to care for HIV, viral hepatitis, TB, STIs and other infectious diseases: Paving the way forward amidst a global pandemic	Panellists: Cary James, World Hepatitis Alliance Andrew Winter, IUSTI Europe Jens Lundgren, CHIP, University of Copenhagen Nicole Seguy, WHO Regional Office for Europe Yazdan Yazdanpanah, ANRS Maladies Infectieuses Emergentes, France Nikoloz Chkhartishvili, Infectious Diseases, AIDS & Clinical Immunology Research Center (IDACIRC), Georgia Paul Sommerfeld, TB Europe Coalition Nikos Dedes, European AIDS Treatment Group (EATG) Ricardo Baptista Leite, MP Portugal, UNITE
19:05-19:15		Conference Call to Action and closing remarks	Daniel Simões, HepHIV2021 Conference Co-chair, Coalition Plus/GAT, Portugal



Supported by Gilead Sciences Europe Ltd who provided funding. Gilead Sciences Europe Ltd. has had no input into the content of the materials and presentations used at this event.



Support provided by ViiV Healthcare



This conference was supported by a grant from MSD